213 related articles for article (PubMed ID: 35617957)
1. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
[TBL] [Abstract][Full Text] [Related]
2. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.
Perlman EJ; Grundy PE; Anderson JR; Jennings LJ; Green DM; Dome JS; Shamberger RC; Ruteshouser EC; Huff V
J Clin Oncol; 2011 Feb; 29(6):698-703. PubMed ID: 21189373
[TBL] [Abstract][Full Text] [Related]
3. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
4. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
[TBL] [Abstract][Full Text] [Related]
8. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
9. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
[TBL] [Abstract][Full Text] [Related]
10. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
11. Copy Number Variations in Wilms Tumor: A Pilot Study From India.
Rahiman EA; Singh M; Bhatia P; Kakkar N; Trehan A; Bansal D
J Pediatr Hematol Oncol; 2020 Jul; 42(5):e299-e304. PubMed ID: 31851072
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Ruteshouser EC; Robinson SM; Huff V
Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
[TBL] [Abstract][Full Text] [Related]
13. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
14. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
15. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
16. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
[TBL] [Abstract][Full Text] [Related]
17. Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.
Stevenson MJ; Phanor SK; Patel U; Gisselbrecht SS; Bulyk ML; O'Brien LL
Dis Model Mech; 2023 Nov; 16(11):. PubMed ID: 37815464
[TBL] [Abstract][Full Text] [Related]
18. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
[TBL] [Abstract][Full Text] [Related]
19. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
20. New approaches to risk stratification for Wilms tumor.
Nelson MV; van den Heuvel-Eibrink MM; Graf N; Dome JS
Curr Opin Pediatr; 2021 Feb; 33(1):40-48. PubMed ID: 33394739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
